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Edited by Richard MaraisAbstract Charge-neutralizing mutation D6.30N of the human
cannabinoid receptor subtype 1 (CB1) and cannabinoid receptor
subtype 2 (CB2) cannabinoid receptors was made to test two
hypotheses: (1) D6.30 may be crucial for the functions of CB1
and CB2 receptors. (2) D6.30 may participate in an ionic lock
with R3.50 that keeps the receptors in an inactive conformation.
Speciﬁc ligand binding and ligand-induced inhibition of for-
skolin-stimulated cAMP accumulation were observed with
human embryonic kidney epithelial cell line (HEK293) cells
expressing wildtype CB1 and CB2, as well as CB1D6.30N and
CB2D6.30N mutant receptors. There was however a decrease
in maximum response of the mutant receptors compared to their
wildtype counterparts, suggesting that D6.30 is essential for full
activation of both CB1 and CB2 receptors. Both CB1D6.30N
and CB2D6.30N demonstrated a level of constitutive activity
no greater than that of their wildtype counterparts, indicating
that either D6.30 does not participate in a salt bridge with
R3.50, or the salt bridge is not critical for keeping cannabinoid
receptors in the inactive conformation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cannabinoid receptors are members of the large family of G
protein-coupled receptors (GPCRs), which are important drug
targets [1,2]. To date, two cannabinoid receptors, cannabinoid
receptor subtype 1 (CB1) and cannabinoid receptor subtype 2
(CB2), have been cloned [3,4]. The CB1 receptor is located in
the central nervous system as well as in the peripheral nervous
system whereas the CB2 receptor has been found almost
uniquely in immune cells [3–6]. This distribution suggests a
possible role for the CB2 receptor in mediating immunomodu-Abbreviations: CB1, cannabinoid receptor subtype 1; CB2, cannabi-
noid receptor subtype 2; GPCR, G protein-coupled receptor; b2AR,
b2-adrenergic receptor; 5-HT2A receptor, 5-hydroxytryptamine (sero-
tonin) receptor 2A; TMH, transmembrane helix; HEK293, human
embryonic kidney epithelial cell line
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doi:10.1016/j.febslet.2006.09.001latory, but not psychoactive eﬀects of cannabinoids, for which
CB1 is the prime target.
D6.30 is located at the cytoplasmic end of transmembrane
helix (TMH6) (Fig. 1), and this residue is highly conserved
amongst many GPCRs. Previous studies have provided evi-
dence for the existence of an interaction that constrains the rel-
ative mobility of the cytoplasmic end of TMH3 and TMH6 in
the inactive state of the b2 adrenergic and 5-hydroxytrypta-
mine (serotonin) receptor 2A (5-HT2A) receptors [7–9]. In a
study of b2AR mutations [7], it was established that the
charge-neutralizing mutations of E6.30 led to spontaneous
activation of the b2AR. Recently, Kobilka and co-workers
also showed that disruption of the ionic lock is necessary but
not suﬃcient for full activation of the b2AR [8]. These investi-
gators, as well as Roth and co-workers, who studied 5-HT2A
receptor [9] proposed that the highly conserved R3.50 at the
cytoplasmic end of TMH3 interacts with D/E6.30 at the cyto-
plasmic end of TMH6 and that this interaction (the ionic lock)
may constitute a common switch governing activation of many
rhodopsin-like GPCRs.
In the current study, we investigated: (1) if D6.30 is crucial
in CB1 and/or CB2 receptor ligand binding and activa-
tion; (2) whether the cannabinoid receptors have the same
ionic lock mechanism observed for other GPCRs. Charge-
neutralizing mutation at position 6.30 (D6.30N) was made
in the CB1 and CB2 receptors to answer the above two
questions.2. Materials and methods
2.1. Materials
Reagents and enzymes used for recombinant DNA experiments were
from Promega (Madison, WI). Lipofectamine, Dulbecco’s Modiﬁed
Eagles’s Medium (DMEM), OPTIMEM medium, fetal bovine serum,
geneticin, L-glutamine, penicillin/streptomycin, and trypsin were from
GIBCO-BRL (Gaithersburg, MD). Anti-CB1 and anti-CB2 polyclonal
antibodies were obtained from Cayman Chemical (Ann Arbor, MI),
and normal goat serum from Vector Laboratories. Fluorescein isothio-
cyanate-conjugated anti-rabbit IgG was obtained from Zymed Labo-
ratories (San Francisco, CA). Disposable glass tubes used for
cannabinoid drug dilution, ligand binding and cAMP accumulation as-
says were purchased from BVA Scientiﬁc (San Antonio, TX). These
tubes were silanized by exposing them to dichlorodimethylsilane (Sig-
ma Chemical Co., St. Louis, MO) vapor for 4 h under vacuum. GF/B
ﬁlters were purchased from Whatman International (Maidstone, UK).
[3H]CP55940 was purchased from Perkin-Elmer (Shelton, CT), while
CP55940, SR141716A and SR144528 were from National Institute
of Drug Abuse (Bethesda, MD). Forskolin and paraformaldehyde
were purchased from Sigma-Aldrich (St. Louis, MO) and Ro 20-
1724 from BIOMOL (Philadelphia, PA). HEK293 cells were obtained
from the American Type Culture Collection (Rockville, MD).blished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic representation of the wildtype human CB1 (a) and CB2 (b) receptors showing the position D6.30, the amino acid mutated in this
study.
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The amino acid numbering system in which residues are indexed rel-
ative to the most conserved residue in that transmembrane helix
(TMH) was used [10]. In this system, the most conserved residue in
the helix is assigned a position index of ‘0.50’. Each identiﬁer starts
with the TMH number, followed by the amino acid position relative
to the reference amino acid in the helix, e.g. R3.50 is the most con-
served residue in helix 3 of the CB1 and CB2 receptors (Fig. 1a and
b) and therefore the residues adjacent to it are D3.49 and Y3.51.
2.3. Site-directed mutagenesis
A 1.4-kb full-length human CB1 and a 1.8-kb full-length human
CB2 gene had, respectively, been subcloned into pRC/CMV (Invitro-
gen, San Diego, CA) to construct the expression plasmids [11,12].
The QuikChange II in vitro Site-directed Mutagenesis Kit (Stratagene,La Jolla, CA) was used to mutate the CB1 and CB2 cannabinoid recep-
tors and the DNA sequences of the mutant plasmids were conﬁrmed
by sequencing. The mutagenic oligonucleotides used were as follows:
CB1D6.30N+: 5 0-CCAGACCAAGCCCGCATGAACATTAGGT-
TAGCCAAGACCC-3 0; CB1D6.30N: 5 0-GGGTCTTGGCTAACC-
TAATGTTCATGCGGGCTTGGTC TGG-30; CB2D6.30N+: 5 0-GG
CCCGAATGAGGCTGAACGTGAGGTTGGCCAA GACCC-3 0;
CB2D6.30N: 5 0-GGGTCTTGGCCAACCTCACGTTCAGCCTC-
ATT CGGGCC-3 0.
2.4. Cell transfection and culture
Human embryonic kidney 293 (HEK293) cells were grown as mono-
layers in Dulbecco’s Modiﬁed Eagle Medium (DMEM) containing
10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, and
100 lg/ml streptomycin in a humidiﬁed atmosphere consisting of 5%
5394 N.M. Nebane et al. / FEBS Letters 580 (2006) 5392–5398CO2 and 95% air, at 37 C. Expression plasmids containing the wild-
type and mutant cannabinoid receptors were stably transfected into
HEK293 cells using lipofectamine, according to manufacturer’s
instructions. Stably transfected cells were selected in culture medium
containing 800 lg/ml geneticin. Having established cell lines stably
expressing wildtype and mutant CB1 and CB2 receptors, the cells were
maintained in growth medium containing 400 lg/ml of geneticin until
needed for experiments.75
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Cells were washed twice with cold phosphate-buﬀered saline (PBS)
consisting of 8.1 mM NaH2PO4, 1.5 mM KH2PO4, 138 mM NaCl,
2.7 mM KCl, pH 7.2, and scraped oﬀ the tissue culture plates. Subse-
quently, the cells were homogenized in membrane buﬀer (50 mM Tris–
HCl, 5 mM MgCl2, 2.5 mM EDTA, pH 7.4) with a Polytron homog-
enizer. After the homogenate was centrifuged at 46000 · g for
30 min at 4 C, the pellet was resuspended in membrane buﬀer and
stored at 80 C. Protein concentrations were determined by Bradford
assay using a BioRad protein reagent kit.0
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402.6. Ligand binding assay
Cannabinoid ligand dilutions were made in binding buﬀer (mem-
brane buﬀer containing 0.5 mg/ml of fatty acid-free bovine serum albu-
min (BSA)) and then added to silanized assay tubes. [3H]CP55940 was
used for competition binding assays. Binding assays were performed as
described previously [11,12].-12 -11 -10 -9 -8 -7 -6 -5
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2.7. Immunoﬂuorescence staining
HEK293 cells stably expressing wildtype and mutant CB1 and CB2
receptors were grown on glass coverslips (Fisher Scientiﬁc) to 60% con-
ﬂuency. Cells were ﬁxed with 4% (v/v) paraformaldehyde for 10 min
and washed three times with 0.1 M PBS, pH 7.4 containing 0.1% fatty
acid-free BSA. The cells were then treated with 0.5% Triton X-100 in
PBS for 10 min, and again washed three times with PBS. Next, they
were incubated with PBS containing 5% normal goat serum/0.05% Tri-
ton X-100 for 1 h at room temperature, and then incubated with anti-
CB1 (for CB1 receptors) and anti-CB2 (for CB2 receptors) antibodies
(Cayman) for 1 h at room temperature. After washing three times with
PBS for 10 min each time, the cells were incubated with ﬂuorescein iso-
thiocyanate-conjugated anti-rabbit IgG (Zymed) for 1 h at room tem-
perature. The coverslips were then washed four times with PBS,
mounted on slides with vectashield (Vector Laboratories), and viewed
with an Olympus I·50 ﬂuorescence microscope.-12 -11 -10 -9 -8 -7 -6 -5
-25
0
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Fig. 2. Comparison of wildtype and mutant CB1 and CB2 receptors2.8. Assay of cAMP accumulation
Cells were grown to conﬂuence, washed twice in PBS containing
0.5 mM EDTA, and then collected in DMEM containing 0.2% (w/v)
fatty acid-free BSA. Assay of cAMP accumulation was performed as
previously described [11,12].for cannabinoid ligand binding. CP55940 was used for competition
binding with [3H]CP55940 on membranes prepared from HEK293 cells
expressing the CB1 wildtype and CB1D6.30N mutant receptors (a), as
well as the CB2 wildtype and CB2D6.30N mutant receptors (b). Data
shown represent the means ± S.E.M. of at least three independent
experiments performed in duplicate.
Table 1
Parameters of [3H]CP55940 binding to wildtype and mutant CB1 and
CB2 receptors stably expressed in HEK293 cells2.9. Constitutive activation
Constitutive activity was measured as the ability of the receptor to
inhibit forskolin-stimulated cAMP accumulation in the absence of can-
nabinoid agonists. The procedures for cell collection and preparation
are the same as described in the previous section. After incubating with
diﬀerent concentrations of forskolin, with and without inverse agonist
(SR141716A for CB1 or SR144528 for CB2), for 10 min at 37 C, the
cells were assayed for cAMP levels and the results were expressed as
fold of basal cAMP accumulation, measured in the absence of for-
skolin.Receptor Kd (nM) Bmax (pmol/mg protein)
CB1 wildtype 1.36 (0.46–4.06) 1.48 ± 0.15
CB1D6.30N 1.17 (0.37–2.19) 1.45 ± 0.23
CB2 wildtype 0.83 (0.24–4.30) 1.46 ± 0.15
CB2D6.30N 1.07 (0.36–1.64) 1.31 ± 0.20
Kd and Bmax values were measured in competition binding experiments
using [3H]CP55940 as radioligand (see Section 2). Kd values are pre-
sented as means (95% conﬁdence intervals) and Bmax values are pre-
sented as means ± S.E.M. of at least three independent experiments
performed in duplicate.2.10. Data analysis
Data from ligand binding and cAMP accumulation assays were ana-
lyzed, and curves generated by using the GraphPad Prism program
(GraphPad Software). The IC50 and EC50 values were determined
through non-linear regression analysis performed with Prism. Kd and
Bmax values were estimated from competition binding experiments
using the following equations: Kd = IC50  L and Bmax = (B0IC50)/L,
where L is the concentration of free radioligand, and B0 is speciﬁcally
bound radioligand [13]. The Ki values were calculated based on the
Cheng–Prusoﬀ equation: Ki = IC50/(1 + L/Kd) [14].3. Results
3.1. Ligand binding assay
Speciﬁc, high aﬃnity binding was observed with membranes
prepared from HEK293 cells transfected with wildtype CB1
and CB2, as well as CB1D6.30N and CB2D6.30N mutant
receptors (Fig. 2a and b). The aﬃnities and Bmax values of both
CB1D6.30N and CB2D6.30N were similar to that of wildtype
CB1 and CB2, respectively (Fig. 2a and b and Table 1).
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The expression of wildtype and mutant receptors on the sur-
face of the cell membrane was examined in an immunoﬂuores-
cent microscopy study. Using anti-CB1 and anti-CB2 primary
antibodies directed against the N-terminal of the CB1 and CB2
receptors, respectively, positive immunoﬂuorescent staining
signals were observed with HEK293 cells stably transfected
with the CB1 and CB2 wildtype receptors, as well as
CB1D6.30N and CB2D6.30N mutant receptors (Fig. 3a, b,
d, and e). These data indicate that these receptors were prop-
erly targeted into the plasma membranes. In contrast, with
mock-transfected HEK293 cells, only extremely faint non-spe-
ciﬁc staining was observed with the use of both anti-CB1
(Fig. 3c) and anti-CB2 (Fig. 3f) antibodies.
3.3. Agonist-induced inhibition of cAMP accumulation
Comparison of wildtype and mutant receptor function (cou-
pling to adenylate cyclase) was done by determining the ability
of CP55940, a cannabinoid receptor agonist, to inhibit for-
skolin-stimulated cAMP accumulation. In cells expressing
wildtype CB1 and CB2 receptors, CP55940 inhibited for-
skolin-stimulated cAMP accumulation in a concentration-
dependent manner (Fig. 4a and b). CP55940 was also able to
inhibit forskolin-stimulated cAMP accumulation in cells
expressing the CB1D6.30N (Fig. 4a) and CB2D6.30N
(Fig. 4b) mutant receptors, although CP55940 inhibited for-
skolin-stimulated cAMP accumulation to a reduced level in
cells expressing these mutant receptors versus their wildtype
counterparts (Fig. 4a and b and Table 2).
3.4. Constitutive activation
To study the possible constitutive activation of the wildtype
and mutant receptors, cells expressing these receptors were as-Fig. 3. Immunoﬂuorescent staining of HEK293 cells expressing wildtype a
receptor-expressing HEK293 cells were grown on glass coverslips, and ﬁxed a
(c) HEK293 cells stained with anti-CB1 antibody; (d) CB2 wildtype; (e) CB2sayed for cAMP accumulation in response to various concen-
trations of forskolin, in the absence of cannabinoid receptor
agonist. In mock-transfected HEK293 cells, HEK293 cells
transfected with CB1 and CB2 wildtype receptors, and
HEK293 cells transfected with two mutant receptors
(CB1D6.30N and CB2D6.30N), forskolin-stimulated cAMP
accumulation in a concentration-dependent manner (Fig. 5a
and b). The level of forskolin-stimulated cAMP accumulation
was lower in cells expressing the CB1 and CB2 wildtype recep-
tors compared to mock-transfected HEK293 cells (Fig. 5a and
b). The level of forskolin-stimulated cAMP accumulation was
also lower in cells expressing CB1D6.30N and CB2D6.30N
mutant receptors than in mock-transfected HEK293 cells
(Fig. 5a and b). In addition, the levels of forskolin-induced
cAMP accumulation in CB1 and CB2 wildtype receptor-con-
taining cells were similar to those observed in CB1D6.30N
and CB2D6.30N expressing cells, respectively (Fig. 5a and b).
As shown in Fig. 6, treatment with the CB1 inverse agonist
SR141716A returned the cAMP level of CB1 wildtype (Fig. 6a)
and CB1D6.30N-expressing cells (Fig. 6b) to levels similar to
those found in mock-transfected cells. Similarly, as shown in
Fig. 7, treatment with the CB2 inverse agonist SR144528 re-
turned the cAMP level of CB2 wildtype (Fig. 7a) and
CB2D6.30N-expressing cells (Fig. 7b) to levels comparable
to those found in mock-transfected cells.4. Discussion
In this study, both CB1D6.30N and CB2D6.30N mutant
receptors maintained their ability to bind cannabinoid ligand,
CP55940. In the cAMP accumulation assay, CP55940 was able
to inhibit forskolin-stimulated cAMP accumulation in thend mutant CB1 and CB2 receptors. Cells from wildtype or mutant
nd stained as described in Section 2: (a) CB1 wildtype; (b) CB1D6.30N;
D6.30N; and (f) HEK293 cells stained with anti-CB2 antibody.
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Fig. 5. Eﬀect of D6.30N mutation on constitutive activation of the
CB1 and CB2 receptors. Mock-transfected HEK293 cells and cells
expressing wild-type and mutant receptors were assayed for cAMP
accumulation in response to various concentrations of forskolin, in the
absence of cannabinoid ligands: (a) mock-transfected HEK293, CB1
wild-type and CB1D6.30N mutant receptor; and (b) mock-transfected
HEK293, CB2 wild-type and CB2D6.30N mutant receptor. The results
were expressed as fold of basal cAMP accumulation, measured in the
absence of forskolin. Data shown represent the means ± S.E.M. of at
least three independent experiments performed in triplicate. The
asterisk () denotes P < 0.05, two-tailed t-test.
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Fig. 4. Comparison of wildtype and mutant CB1 (a) and CB2 (b)
receptors for agonist-induced inhibition of forskolin-stimulated cAMP
accumulation. Wildtype and mutant receptor-expressing HEK293 cells
were used to test CP55940-induced inhibition of forskolin-stimulated
cAMP accumulation. The results were expressed as a percentage of
forskolin-stimulated cAMP accumulation, measured in the absence of
CP55940. Data shown represent the means ± S.E.M. of at least three
independent experiments performed in triplicate. The asterisk ()
denotes P < 0.05, two-tailed t-test.
Table 2
Comparison of wildtype and mutant CB1 and CB2 receptors for their
EC50 and maximum response values in assays of CP55940-induced
inhibition of forskolin-stimulated cAMP accumulation
Receptor EC50 (95% CI), nM Maximum response
(95% CI), %
CB1 wildtype 4.16 (2.10–8.26) 72.40 (70.62–74.14)
CB1D6.30N 2.61 (2.06–3.30) 48.78 (48.31–49.15)
CB2 wildtype 1.23 (0.69–2.32) 68.07 (67.43–68.69)
CB2D6.30N 1.27 (1.09–1.39) 44.15 (42.20–46.07)
Data presented are means (95% conﬁdence intervals) from at least
three independent experiments performed in triplicate.
5396 N.M. Nebane et al. / FEBS Letters 580 (2006) 5392–5398CB1D6.30N and CB2D6.30N mutants, similar to the wildtype
CB1 and CB2 receptors, indicating that the mutant receptors
maintained their overall functional properties. There is how-
ever a decrease in maximum response of the mutant receptors
compared to their wildtype counterparts. These data therefore
demonstrated that D6.30 is not crucial for ligand binding but
is essential for full activation of both CB1 and CB2 receptors.
A possible explanation as to why CP55940 is less eﬀective at
inhibiting forskolin-induced cAMP accumulation in the
CB1D6.30N- and CB2D6.30N-transfected cells compared tothe CB1 and CB2 wildtype-transfected cells is an altered G
protein–receptor interaction. Based on the location of D6.30
which is at the cytoplasmic end of TMH6 in both CB1 and
CB2, and the fact that [3H]CP55940 binding to the mutant
receptors was unaltered, the reduced inhibition of forskolin-in-
duced cAMP accumulation for the mutant receptors is more
likely due to conformational changes, than direct changes in li-
gand–receptor interactions. The D6.30N mutations probably
cause a conformational change in the receptor that alters its
interaction with G protein.
In this study, we established constitutive activity of wildtype
and mutant receptors by comparing the level of forskolin-stim-
ulated cAMP accumulation in HEK293 cells transfected with
receptors to that in mock-transfected HEK293 cells. Cells
expressing wildtype CB1 and CB2 receptors exhibited a lower
level of forskolin-stimulated cAMP accumulation than mock-
transfected HEK293 cells, indicating constitutive activity.
These data conﬁrmed that CB1 and CB2 receptors are consti-
tutively active, as shown in previous studies [15,16]. Similarly,
the level of forskolin-stimulated cAMP accumulation was low-
er in cells expressing CB1D6.30N and CB2D6.30N mutant
receptors versus in mock-transfected HEK293 cells, indicating
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Fig. 6. Eﬀect of CB1 inverse agonist SR141716A on constitutive
activation of CB1 wild-type and mutant receptors. Cells expressing
CB1 wild-type (a) and CB1D6.30N (b) mutant receptors were assayed
for cAMP accumulation in response to various concentrations of
forskolin, with and without treatment with the inverse agonist
SR141716A (0.3 lM). The results were expressed as fold of basal
cAMP accumulation, measured in the absence of forskolin. Data
shown represent the means ± S.E.M. of at least three independent
experiments performed in triplicate. The asterisk () denotes P < 0.05,
two-tailed t-test.
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Fig. 7. Eﬀect of CB2 inverse agonist SR144528 on constitutive
activation of CB2 wild-type and mutant receptors. Cells expressing
CB2 wild-type (a) and CB2D6.30N (b) mutant receptors were assayed
for cAMP accumulation in response to various concentrations of
forskolin, with and without treatment with the inverse agonist
SR144528 (0.3 lM). The results were expressed as fold of basal cAMP
accumulation, measured in the absence of forskolin. Data shown
represent the means ± S.E.M. of at least three independent experi-
ments performed in triplicate. The asterisk () denotes P < 0.05, two-
tailed t-test.
N.M. Nebane et al. / FEBS Letters 580 (2006) 5392–5398 5397constitutive activity of these mutant receptors. Furthermore,
the constitutive activity of the CB1D6.30N and CB2D6.30N
receptors was identical to that in their wildtype counterparts.
We also compared the level of forskolin-stimulated cAMP
accumulation in receptor-containing cells treated with and
without inverse agonist. SR141716A and SR144528 are inverse
agonists speciﬁc for CB1 and CB2 receptors, respectively. An
inverse agonist should shift a constitutively active receptor to
an inactive conformation. Therefore, to conﬁrm constitutive
activity, pretreatment with SR141716A or SR144528 should
increase the lowered levels of forskolin-stimulated cAMP accu-
mulation in the CB1 and CB2 receptors, respectively, back to
the levels observed in mock-transfected HEK293 cells. The ex-
pected results with the two inverse agonists were observed in
Figs. 6 and 7, thus conﬁrming the constitutive activity of wild-
type as well as D6.30N mutant CB1 and CB2 cannabinoid
receptors.
It has been suggested that activation of the cannabinoid CB1
receptor may involve a W6.48/F3.36 rotamer toggle switch
[17,18]. In rhodopsin, which lacks constitutive activity,
W6.48 is ﬂanked by aromatic residues at positions I4
(F6.44) and I+3 (Y6.51), while in CB1 and CB2, the residuesI4 and I+3 to W6.48 are leucine or valine (L6.44 and L6.51
for CB1, and L6.44 and V6.51 for CB2). Conformational
memories (CM) calculation on wildtype CB1 TMH6 revealed
that the presence of leucines at positions 6.44 and 6.51 pro-
vides W6.48 with greater conformational mobility [17]. There-
fore it is likely that the W6.48/F3.36 rotamer toggle switch is
the activation mechanism in constitutively active cannabinoid
receptors in which the salt bridge is not important. In other
words, the lack of aromatic residues at 6.44 and 6.51 probably
results in a conformational mobility of TMH6, which may
counteract the putative inactivation by the salt bridge interac-
tion between TMH3 and TMH6, explaining our result that
breaking the proposed salt bridge has no impact on the consti-
tutive activity of CB1 and CB2.
In summary, in this study by creating charge-neutralizing
mutation D6.30N, we have found that: (1) D6.30 is not crucial
for the ligand binding but important for the full activation of
CB1 and CB2. (2) D6.30 either does not participate in a salt
bridge between R3.50 and D6.30, or the salt bridge is not
important for keeping CB1 and CB2 in an inactive conforma-
tion. The most important conclusion of this study is that a salt
5398 N.M. Nebane et al. / FEBS Letters 580 (2006) 5392–5398bridge that has been proposed to hold the cytoplasmic ends of
TMH3 and TMH6 together and to keep the receptor in the
inactive state is not important for certain GPCRs, such as can-
nabinoid receptors, which are already highly constitutively ac-
tive in their wildtypes.
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